New Molecular Entities (NMEs) & Utilization Characterization

New Molecular Entities Duration of Follow Up for New Molecular Entities Approved in 2005, 2006, and 2007 Duration of Follow Up for New Molecular Entities Approved in 2007: A Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2008 and 2009 Duration of Follow Up for New Molecular Entities Approved in 2010, 2012, and 2013 Duration of Follow Up for New Molecular Entities Approved in 2011 Duration of Follow Up for New Molecular Entities Approved in 2014 and 2015 Duration of Follow Up for New Molecular Entities Approved in 2016 Duration of Follow Up for New Molecular Entities Approved in 2017: A Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2017: An Updated Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2018: A Descriptive Analysis Duration of Follow Up for New Molecular Entities Approved in 2019: A Descriptive Analysis Characterization of Users of New Molecular Entities Approved in 2021 in TriNetX: A Descriptive Analysis

Presentation: Early Post-Approval Surveillance of New Molecular Entity Uptake in the Sentinel Distributed Database Presentation: Early Uptake of New Molecular Entities Approved in 2017 in a Multisite National US Healthcare Data Network